A Phase II Open-label Study Evaluating Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma
Latest Information Update: 29 Jan 2025
At a glance
- Drugs Valemetostat (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Acronyms VALYM
Most Recent Events
- 24 Jan 2025 Planned End Date changed from 1 Oct 2024 to 1 Oct 2026.
- 02 Dec 2024 According to a Daiichi Sankyo Company media release, data from this trial will be presented in a Poster session on Monday, December 9, 6:00 - 8:00 pm at American Society of Hematology (#ASH24) Annual Meeting.
- 02 Jun 2024 This trial has been completed in France.